Phase 3 Readout~month

Phase 3 Topline: An Open-Label Study to Evaluate Safety of Pitolisant in Participants With Prader-Willi Syndrome

Indication
Prader-Willi Syndrome

Other upcoming events for MBX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Fol
Patent ExpiryPatent/Exclusivity Expiry: WAKIX

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label Study to Evaluate Safety of Pitolisant in Participants With Prader-Willi Syndrome — MBX Phase 3 Readout | BioSniper